SCHEMBL4660107

SCHEMBL4660107

COC(=O)C(C)(C#N)C(c1cnc2ccccc2c1)c1ccccc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 11/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 3/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
NFKB1 P19838 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
PDE4D Q08499 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
TRPV1 Q8NER1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4659962 0.91 PDE4D (0.43) ALPLSMN1; SMN2KDM4ELMNAALDH1A1
SCHEMBL4660093 0.84 PDE4D (0.40) ALPLSMN1; SMN2KDM4ELMNAALDH1A1
SCHEMBL4660062 0.80 PDE4D (0.43) ALPLSMN1; SMN2KDM4ELMNAALDH1A1
SCHEMBL4660066 0.80 PDE4D (0.43) ALPLSMN1; SMN2KDM4ELMNAALDH1A1
SCHEMBL4661464 0.78 ESR1 (0.42) SMN1; SMN2KDM4ELMNAGAANPC1
SCHEMBL13938655 0.77 ESR1 (0.54) SMN1; SMN2KDM4ELMNAALDH1A1GAA
SCHEMBL4135203 0.77 ESR1 (0.54) SMN1; SMN2KDM4ELMNAALDH1A1GAA
SCHEMBL4659922 0.77 ALPL (0.42) ALPLSMN1; SMN2KDM4ELMNAALDH1A1
SCHEMBL4662623 0.77 ESR1 (0.41) SMN1; SMN2KDM4ELMNAGAANPC1
SCHEMBL4662626 0.76 ESR1 (0.41) SMN1; SMN2KDM4ELMNAGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620102-B1 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS WYETH CORP (US) 2008-12-24 EP disclosed
US-20070299105-A1 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use WYETH (US) 2007-12-27 US disclosed
EP-1620102-A2 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS Wyeth (US) 2006-02-01 EP disclosed
US-20050256132-A1 Use of ER selective NF-kB inhibitors for the treatment of sepsis WYETH (US) 2005-11-17 US disclosed
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use WYETH 2005-01-06 US disclosed
WO-2004099150-A2 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS WYETH (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256132-A1 Use of ER selective NF-kB inhibitors for the treatment of sepsis NFKBIA, IKBKB, NFKB2 ALPL 3297/4885SMN1; SMN2 3620/4885KDM4E 1711/4885
US-20070299105-A1 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use HCAR2, PCCA, MCCC2 ALPL 3967/4885SMN1; SMN2 1893/4885KDM4E 2551/4885
US-20050004164-A1 2-Cyanopropanoic acid amide and ester derivatives and methods of their use HCAR2, PCCA, MCCC2 ALPL 3792/4885SMN1; SMN2 1969/4885KDM4E 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.